Literature DB >> 30837817

Trimethoprim/Sulfamethoxazole and Moxifloxacin Therapy for a Pediatric Stenotrophomonas Maltophilia Ventriculoperitoneal Shunt Infection.

Eric R Gregory, Sam B Osborne, Brian M Gardner, Robert A Broughton.   

Abstract

Stenotrophomonas maltophilia is an increasingly prevalent cause of nosocomial infections. This report describes a 5-month-old male diagnosed with a S maltophilia ventriculoperitoneal shunt infection after a neurosurgical procedure. Intravenous trimethoprim/sulfamethoxazole and moxifloxacin successfully treated the patient. A literature review revealed a scarcity of similar reports, with none using moxifloxacin as an effective concomitant treatment with trimethoprim-sulfamethoxazole.

Entities:  

Keywords:  Stenotrophomonas maltophilia; moxifloxacin; pediatric; ventriculoperitoneal shunt

Year:  2019        PMID： 30837817      PMCID： PMC6397010          DOI： 10.5863/1551-6776-24.1.61

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


  15 in total

1.  Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?

Authors:  A C Galles; R N Jones; H S Sader
Journal:  J Chemother       Date:  2008-02       Impact factor: 1.714

2.  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors:  Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

3.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

4.  Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia.

Authors:  Sheryl A Zelenitsky; Harris Iacovides; Robert E Ariano; Godfrey K M Harding
Journal:  Diagn Microbiol Infect Dis       Date:  2005-01       Impact factor: 2.803

Review 5.  Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review.

Authors:  Matthew E Falagas; Politimi-Eleni Valkimadi; Yu-Tsung Huang; Dimitrios K Matthaiou; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2008-07-28       Impact factor: 5.790

6.  Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.

Authors:  Kyriaki Kanellakopoulou; Alexandra Pagoulatou; Konstantinos Stroumpoulis; Marianthi Vafiadou; Hariklia Kranidioti; Helen Giamarellou; Evangelos J Giamarellos-Bourboulis
Journal:  J Antimicrob Chemother       Date:  2008-03-18       Impact factor: 5.790

7.  Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.

Authors:  J W C Alffenaar; R van Altena; H J Bökkerink; G J Luijckx; D van Soolingen; R E Aarnoutse; T S van der Werf
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

8.  Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin.

Authors:  John S Bradley; Ralph E Kauffman; Dainius A Balis; Ciaran M Duffy; Peter G Gerbino; Samuel D Maldonado; Gary J Noel
Journal:  Pediatrics       Date:  2014-06-02       Impact factor: 7.124

9.  Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.

Authors:  Mark A Toleman; Peter M Bennett; David M C Bennett; Ronald N Jones; Timothy R Walsh
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883

10.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more
  2 in total

1.  Stenotrophomonas maltophilia: An emerging opportunistic nosocomial pathogen in a tertiary care hospital in Al Batinah North Governorate, Oman.

Authors:  Mohan B Sannathimmappa; Vinod Nambiar; Rajeev Aravindakshan; Nashwa M Al-Kasaby
Journal:  Sultan Qaboos Univ Med J       Date:  2021-03-15

2.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.